+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Uterine Cancer Therapeutics & Diagnostics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 187 Pages
  • February 2024
  • Infogence Global Research
  • ID: 5820277

The endometrial biopsy is the most common technique used to obtain endometrial tissue, and the evaluation of endometrial histology has been the gold standard for determining the status of the endometrium

The Global Uterine Cancer Therapeutics & Diagnostics Market is estimated to be USD 21.58 Bn in 2023 and is expected to reach USD 29.97 Bn by 2028 growing at a CAGR of 6.79%.

Uterine cancer, also known as endometrial cancer, develops in the lining of the uterus. It is the most common gynecologic cancer in women, and its incidence rate is increasing worldwide. The American Cancer Society estimates that the cancer of the uterus in the United States in 2023 to be around 66,200 new cases.

Several types of drugs are used to treat uterine cancer, depending on the cancer stage and other individual factors. Some common drugs used for the treatment of uterine cancer are Chemotherapy drugs, Hormone therapy drugs, Targeted therapy drugs, Immunotherapy drugs, and others.

Several causes, such as Obesity, the background of endometrial, other cancers, hormonal imbalances, endometrial hyperplasia, etc., could cause the rising frequency of uterine cancer. About 70% of uterine cancer cases are linked to obesity. With the increasing rate of obesity and lifestyle diseases, the risk of uterine cancer is anticipated to increase, thereby boosting the market demand.

However, the high cost of therapeutics & diagnostics for uterine cancer hampers the market. In addition, the side effects associated with the therapeutics, such as hair loss, cancer pains, etc., further restrict the market growth.
  • Advancements in cancer screening and treatment methods are anticipated to create lucrative opportunities for the market. For instance, in 2023, US FDA approved Jemperli's treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer.

Market Segmentations

  • The Global Uterine Cancer Therapeutics & Diagnostics Market is segmented based on Product, Cancer Type, and Geography.
  • By Product, the market is classified into Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma. The endometrial adenocarcinoma segment is expected to grow due to the increasing burden of this type of cancer. According to Cancer.gov, endometrial adenocarcinoma is the most common type of uterine cancer in women, accounting for approximately 80% of cases, and the severity can vary. The growing incidence of endometrial carcinoma is linked to increasing rates of obesity among women.
  • By Cancer Type, the market is classified into Therapeutics and Diagnostics. The Therapeutics segment is increasing due to advances in medical research and the development of new treatments. Targeted therapies and immunotherapy have resulted in treating uterine cancer, and ongoing research is focused on developing new therapies that can further improve patient outcomes.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. Americas segment holds the largest market share in the Global Uterine Cancer Therapeutics & Diagnostics Market. This is due to a combination of factors, including the presence of major market players and well-established healthcare infrastructure. The region has a strong focus on medical research and innovation. Additionally, several initiatives and organizations in the Americas region focus on raising uterine cancer awareness and improving access to screening and treatment.

Recent Development

  • The FDA approved Jemperli (dostarlimab-gxly) for patients with recurrent or advanced endometrial cancer and the biomarker mismatch repair-deficient. This is the first immunotherapy approved for patients with this type of cancer. - April 2021
  • FDA Approved Merck’s Keytruda Treatment for Endometrial Carcinoma.- June 2021

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Danaher, Elekta AB, Eli Lilly and Co., F. Hoffmann-La Roche, GSK, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Uterine Cancer Therapeutics & Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Uterine Cancer Therapeutics & Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Uterine Cancer Therapeutics & Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Increasing Prevalence of Uterine Cancer
4.2.2 Rising Awareness of Women’s Health
4.2.3 Rising Focus of Government on Providing Adequate Healthcare Solutions
4.3 Restraints
4.3.1 High Cost Associated with the Therapeutics & Diagnosis
4.4 Opportunities
4.4.1 Increasing Advancements in Cancer Screening and Treatment Methods
4.4.2 Growing Demand for Personalized Medicine
4.5 Challenges
4.5.1 Side Effects and Severe Toxicity of the Medications
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Uterine Cancer Therapeutics & Diagnostics Market, By Product
6.1 Introduction
6.2 Therapeutics
6.2.1 Surgery
6.2.2 Immunotherapy
6.2.3 Radiation Therapy
6.2.4 Chemotherapy
6.2.5 Others
6.3 Diagnostics
6.3.1 Biopsy
6.3.2 Pelvic Ultrasound
6.3.3 Hysteroscopy
6.3.4 Dilation and Curettage
6.3.5 CT Scan
7 Global Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type
7.1 Introduction
7.2 Endometrial Adenocarcinoma
7.3 Adenosquamous Carcinoma
7.4 Papillary Serous Carcinoma
7.5 Uterine Sarcoma
8 Americas' Uterine Cancer Therapeutics & Diagnostics Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe's Uterine Cancer Therapeutics & Diagnostics Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Italy
9.9 Ireland
9.10 Luxemburg
9.11 Netherlands
9.12 Norway
9.13 Poland
9.14 Russia
9.15 Spain
9.16 Sweden
9.17 Switzerland
9.18 United Kingdom
9.19 Rest of Europe
10 Middle East and Africa's Uterine Cancer Therapeutics & Diagnostics Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Nigeria
10.5 Qatar
10.6 Saudi Arabia
10.7 South Africa
10.8 United Arab Emirates
10.9 Rest of MEA
11 APAC's Uterine Cancer Therapeutics & Diagnostics Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
13 Company Profiles
13.1 Abbott Laboratories
13.1.1 Company Overview
13.1.2 Company Snapshot
13.1.3 Product Overview
13.1.4 Business Overview
13.1.5 SWOT Analysis
13.1.6 Recent Developments
13.2 AbbVie Inc.
13.2.1 Company Overview
13.2.2 Company Snapshot
13.2.3 Product Overview
13.2.4 Business Overview
13.2.5 SWOT Analysis
13.2.6 Recent Developments
13.3 Ability Pharma
13.3.1 Company Overview
13.3.2 Company Snapshot
13.3.3 Product Overview
13.3.4 Business Overview
13.3.5 SWOT Analysis
13.3.6 Recent Developments
13.4 AstraZeneca PLC
13.4.1 Company Overview
13.4.2 Company Snapshot
13.4.3 Product Overview
13.4.4 Business Overview
13.4.5 SWOT Analysis
13.4.6 Recent Developments
13.5 Bayer Ag
13.5.1 Company Overview
13.5.2 Company Snapshot
13.5.3 Product Overview
13.5.4 Business Overview
13.5.5 SWOT Analysis
13.5.6 Recent Developments
13.6 BioMerieux SA
13.6.1 Company Overview
13.6.2 Company Snapshot
13.6.3 Product Overview
13.6.4 Business Overview
13.6.5 SWOT Analysis
13.6.6 Recent Developments
13.7 Clovis Oncology
13.7.1 Company Overview
13.7.2 Company Snapshot
13.7.3 Product Overview
13.7.4 Business Overview
13.7.5 SWOT Analysis
13.7.6 Recent Developments
13.8 Danaher Corp.
13.8.1 Company Overview
13.8.2 Company Snapshot
13.8.3 Product Overview
13.8.4 Business Overview
13.8.5 SWOT Analysis
13.8.6 Recent Developments
13.9 Elekta AB
13.9.1 Company Overview
13.9.2 Company Snapshot
13.9.3 Product Overview
13.9.4 Business Overview
13.9.5 SWOT Analysis
13.9.6 Recent Developments
13.10 Eli Lilly and Co.
13.10.1 Company Overview
13.10.2 Company Snapshot
13.10.3 Product Overview
13.10.4 Business Overview
13.10.5 SWOT Analysis
13.10.6 Recent Developments
13.11 F. Hoffmann-La Roche Ag
13.11.1 Company Overview
13.11.2 Company Snapshot
13.11.3 Product Overview
13.11.4 Business Overview
13.11.5 SWOT Analysis
13.11.6 Recent Developments
13.12 GSK PLC
13.12.1 Company Overview
13.12.2 Company Snapshot
13.12.3 Product Overview
13.12.4 Business Overview
13.12.5 SWOT Analysis
13.12.6 Recent Developments
13.13 Hologic, Inc.
13.13.1 Company Overview
13.13.2 Company Snapshot
13.13.3 Product Overview
13.13.4 Business Overview
13.13.5 SWOT Analysis
13.13.6 Recent Developments
13.14 Johnson & Johnson
13.14.1 Company Overview
13.14.2 Company Snapshot
13.14.3 Product Overview
13.14.4 Business Overview
13.14.5 SWOT Analysis
13.14.6 Recent Developments
13.15 Merck & Co., Inc.
13.15.1 Company Overview
13.15.2 Company Snapshot
13.15.3 Product Overview
13.15.4 Business Overview
13.15.5 SWOT Analysis
13.15.6 Recent Developments
13.16 Pfizer Inc.
13.16.1 Company Overview
13.16.2 Company Snapshot
13.16.3 Product Overview
13.16.4 Business Overview
13.16.5 SWOT Analysis
13.16.6 Recent Developments
13.17 Sanofi SA
13.17.1 Company Overview
13.17.2 Company Snapshot
13.17.3 Product Overview
13.17.4 Business Overview
13.17.5 SWOT Analysis
13.17.6 Recent Developments
13.18 Siemens Healthineers Ag
13.18.1 Company Overview
13.18.2 Company Snapshot
13.18.3 Product Overview
13.18.4 Business Overview
13.18.5 SWOT Analysis
13.18.6 Recent Developments
13.19 Sun Pharmaceutical Industries Ltd.
13.19.1 Company Overview
13.19.2 Company Snapshot
13.19.3 Product Overview
13.19.4 Business Overview
13.19.5 SWOT Analysis
13.19.6 Recent Developments
13.20 Takeda Pharmaceutical Co. Ltd.
13.20.1 Company Overview
13.20.2 Company Snapshot
13.20.3 Product Overview
13.20.4 Business Overview
13.20.5 SWOT Analysis
13.20.6 Recent Developments
14 Appendix
14.1 Self-Assessment Form

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Ability Pharma
  • AstraZeneca PLC
  • Bayer Ag
  • BioMerieux SA
  • Clovis Oncology
  • Danaher Corp.
  • Elekta AB
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ag
  • GSK PLC
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers Ag
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.